ClinicalTrials.gg
CompletedNCT01743989ENESTPathUpdated Jul 15, 2021Results posted

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.

A Phase 3 interventional study of Nilotinib in Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), sponsored by Novartis Pharmaceuticals. Completed at 208 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
620
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
2nd of 66
620 · median 55
Started
2013
with 10 others
Phase 3
15 of 66
none open now
Registered
39th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 2nd largest by enrollment, is one of 11 that started in 2013, is one of 15 in phase 3, and was the 39th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

This study aimed to assess the optimal duration of nilotinib 300 mg twice daily (BID) consolidation treatment in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), in order that patients remained in treatment-free remission (≥MR4.0) without molecular relapse 12 months after starting the Treatment-Free Remission (TFR) phase.

Read the detailed description

This was a prospective, randomized, open-label, multicenter Phase III study. The study design was made up of 3 phases:

  • Nilotinib induction phase: 12 months
  • Nilotinib consolidation phase: 12 or 24 months, depending on randomization
  • Nilotinib treatment-free remission (TFR) phase: 24 or 36 months, depending on randomization.

Subjects were enrolled into the study and were treated with nilotinib 300mg twice daily (BID) for 24 months, during the induction (12 months) and consolidation (12 months) phases. At the end of the first 24 months of treatment, participants achieving a sustained molecular response (defined as ≥ MR4.0, in 4 out of 5 real-time quantitative polymerase chain reaction (RQ-PCR) assessments, including the last assessment, in the last 12 months) were randomized on a 1:1 basis to either:

  1. suspend nilotinib treatment immediately and enter the TFR phase for 36 months (Nilotinib 24-month treatment arm), or
  2. continue nilotinib treatment for a further 12 months (post-randomization consolidation phase), then suspend treatment and enter the TFR phase for 24 months (Nilotinib 36-month treatment arm).

Participants not achieving a sustained molecular response at 24 months from treatment start were not eligible for randomization and were treated at the discretion of the investigator according to standard practice. Information on survival, stem cell transplantation, and status of the patient's disease was collected until death or until 5 years from study entry, whichever came first. Additionally, for Nilotinib 36-month treatment arm, participants who did not achieve a sustained molecular response at 36 months from treatment start, discontinued from the study and were treated according to standard practice and followed up until death or until 5 years from study entry, whichever came first.

Participants relapsing during the TFR phase entered the nilotinib re-treatment phase of the study, and were re-treated with the same dose of nilotinib as they were on before the TFR phase. These patients remained on study until the completion of the 5-year study period unless prematurely withdrawn and discontinued from the study for any reason specified in the Protocol.

03

Conditions studied

  • Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Keywords

  • Adult
  • Chronic myelogenous leukemia (CML)
  • Chronic myeloid leukemia (CML)
  • Chronic myelocytic leukemia (CML)
  • Acute Lymphoblastic Leukemia (ALL) Philadelphia chromosome positive
  • Acute Lymphoid Leukemia
  • Suboptimal molecular response
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Confirmed diagnosis of chronic phase Ph+ CML
  • Previous treatment with imatinib for a minimum of 2 years;
  • Patient in complete cytogenetic response;

Key Exclusion Criteria:

  • Previous achievement of MR4.0 at study entry;
  • Previous treatment with other target cells inhibitors other than imatinib;
  • Patients with any history of detectable atypical Leukemia transcripts or patients with detectable atypical leukemia transcripts at screening;
  • Previous anticancer agents for Chronic myeloid leukemia other than imatinib except for cytoreduction;
  • Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol;
  • History of other active within the 5 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively;
  • Patients who have not recovered from prior surgery;
  • Treatment with other agents within 4 weeks of Day 1;
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug

Other inclusion/exclusion criteria might apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
620 participants (actual)

Study arms

  • Experimental
    Nilotinib 24-month treatment

    Participants were treated with nilotinib 300mg BID for 24 months and, thereafter, entered the 36-month TFR phase

    Drug: Nilotinib

  • Experimental
    Nilotinib 36-month treatment

    Participants were treated with nilotinib 300mg BID for 36 months and, thereafter, entered the 24-month TFR phase

    Drug: Nilotinib

  • Experimental
    Not randomized

    Participants were treated with nolotinib 300mg BID for 24 months, but did not achieve a sustained molecular response after 24 months of treatment.

    Drug: Nilotinib

Interventions

  • Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.

    Also known as: AMN107

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse 12 Months After Entering the TFR Phase

    Number of participants who remained in TFR (≥molecular response (MR) 4.0) without molecular relapse 12 months after entering the TFR phase (without re-starting nilotinib therapy) divided by the number of participants who entered the TFR phase and multiplied by 100. Molecular relapse during TFR is defined as the loss of major molecular response (MMR), or the confirmed loss of MR4.0 (defined by 3 consecutive tests less than MR4.0 assessed at 3 consecutive visits during TFR phase). Participants dropping out early from the study during the TFR phase were considered as unsuccessful TFR. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL. MR4.0 is defined as either detectable disease≤0.01% BCR-ABL or undetectable disease in cDNA with≥10,000 ABL transcripts

    Time frame: 12 months after entering the TFR phase, which is after 36 months from study treatment start for Nilotinib 24-month treatment arm and after 48 months from study treatment start for Nilotinib 36-month treatment arm

Secondary outcomes

  1. Cumulative Incidence of MMR During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry

    Number of participants who were in MMR during pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.

    Time frame: From baseline up to 24 months after study treatment start

  2. Cumulative Incidence of MMR During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry

    Number of participants who were in MMR during post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.

    Time frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start

  3. Cumulative Incidence of MR4.0 During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry

    Number of participants who were in MR4.0 during the pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

    Time frame: From baseline up to 24 months after study treatment start

  4. Cumulative Incidence of MR4.0 During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry

    Number of participants who were in MR4.0 during the post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

    Time frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start

  5. Cumulative Incidence of MR4.5 During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry

    Number of participants who were in MR4.5 during the pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

    Time frame: From baseline up to 24 months after study treatment start

  6. Cumulative Incidence of MR4.5 During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry

    Number of participants who were in MR4.5 during the post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

    Time frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start

  7. Cumulative Incidence of MMR During the Pre-randomization Induction/Consolidation Phase

    Number of participants who were in MMR during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.

    Time frame: From baseline up to 24 months after study treatment start

  8. Cumulative Incidence of MMR During the Post-randomization Consolidation Phase

    Number of participants who were in MMR during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.

    Time frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start

  9. Cumulative Incidence of MR4.0 During the Pre-randomization Induction/Consolidation Phase

    Number of participants who were in MR4.0 during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

    Time frame: From baseline up to 24 months after study treatment start

  10. Cumulative Incidence of MR4.0 During the Post-randomization Consolidation Phase

    Number of participants who were in MR4.0 during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

    Time frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start

  11. Cumulative Incidence of MR4.5 During the Pre-randomization Induction/Consolidation Phase

    Number of participants who were in MR4.5 during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

    Time frame: From baseline up to 24 months after study treatment start

  12. Cumulative Incidence of MR4.5 During the Post-randomization Consolidation Phase

    Number of participants who were in MR4.5 during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

    Time frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start

  13. Percentage of Participants Who Were in MMR During TFR Phase

    Number of participants who were in MMR at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.

    Time frame: From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm

  14. Percentage of Participants Who Were in MR4.0 During the TFR Phase

    Number of participants who were in MR4.0 at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

    Time frame: From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotininb 36-months treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-months treatment arm

  15. Percentage of Participants Who Were in MR4.5 During the TFR Phase

    Number of participants who were in MR4.5 at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

    Time frame: From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotininb 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm

  16. BCR-ABL Ratio (Expressed as a Percentage) During the Induction/Consolidation Phase

    BCR-ABL transcript ratio by international scale (IS) (expressed as a percentage) during the induction/consolidation phase. Participants randomized to Nilotinib 36-month treatment arm had 12-month additional consolidation phase (post-randomization).

    Time frame: From baseline up to 24 months after study treatment start for Nilotinib 24-month treatment arm and Not randomized participants; and up to 36 months after study treatment start for Nilotinib 36-month treatment arm.

  17. BCR-ABL Ratio (Expressed as a Percentage) During the TFR Phase

    BCR-ABL/control gene (ABL) transcript ratio by international scale (IS) (expressed as a percentage) during the TFR phase. BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase.

    Time frame: From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm

  18. BCR-ABL Ratio (Expressed as a Percentage) During the Nilotinib Re-treatment Phase

    BCR-ABL/control gene (ABL) transcript ratio by international scale (IS) (expressed as a percentage) during the nilotinib re-treatment phase. BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes.

    Time frame: From Day 1 after entering the re-treatment phase up to 24 months after entering re-treatment phase for Nilotinib 36-month treatment arm and 36 months after entering the re-treatment phase for Nilotinib 24-month treatment arm

  19. Progression-free Survival (PFS) During the TFR Phase of the Study.

    PFS is defined as the time from the date of start of the nilotinib TFR phase to the date of acelerated phase/blast crisis (AP/BC) or death, whichever came first. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotini 24-month treatment arm had a maximum of 36 months of TFR phase. Patients not known to have recurred or died on or before the cut-off date for PFS analysis were censored at the date of their last assessment (cytogenetic, hematology or extramedullary) for patients who were on study, and at the date of last contact for patients who were in follow-up.

    Time frame: From the start of the TFR phase to progression to AP/BC or death up to 24 months after entering TFR phase for Nilotininb 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm

  20. Treatment -Free Survival (TFS) During the TFR Phase of the Study

    TFS is defined as the time from the start of the TFR phase to the date of the earliest of the following: loss of MMR, confirmed loss of MR4.0,re-start of nilotinib treatment, progression to AP/BC, or death from any cause. Patients not known to have had any of the events on or before the cut-off date were censored at the earlier of the date of their last assessment for patients who were still on study and the date of last contact for patients who were in follow-up. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1%BCR-ABL. MR4.0 is defined as either detectable disease ≤0.01%BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

    Time frame: From the start of the TFR phase to the date of occurrence of treatment-free survival event, up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm

  21. Overall Survival (OS) Rate During the TFR Phase of the Study.

    OS is defined as the time from start of the TFR phase to the time of death due to any cause. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotini 24-month treatment arm had a maximum of 36 months of TFR phase. For participants without any event on or before the cut-off date, survival time will be censored at the date of their last assessment for patients who are still on study, and at the date of last contact for patients who are in follow-up.

    Time frame: From the start of the TFR phase to death due to any cause, assessed up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm

07

Results

Posted Jul 15, 2021

Participant flow

Treatment Phase
Participant flow — Treatment Phase
MilestoneNilotinib 24-month TreatmentNilotinib 36-month TreatmentNot Randomized
Started120119381
Participants who signed informed consent120118381
Completed1191040
Not completed115381
Withdrew: Unstable mr4.006263
Withdrew: Adverse event0467
Withdrew: Withdrawal by subject1328
Withdrew: Death013
Withdrew: Abnormal laboratory value(s)003
Withdrew: Protocol deviation003
Withdrew: Pregnancy002
Withdrew: Lost to follow-up002
Withdrew: Abnormal test procedure result(s)001
Withdrew: Administrative problems001
Withdrew: New cancer (cml) therapy010
Withdrew: Physician decision003
Withdrew: Patient non-compliance to treatment003
Withdrew: Not randomized by mistake001
Withdrew: Included by mistake001
TFR Phase
Participant flow — TFR Phase
MilestoneNilotinib 24-month TreatmentNilotinib 36-month TreatmentNot Randomized
Started1191040
Completed37360
Not completed82680
Withdrew: Relapse (loss of mmr/confirmed loss of mr4.0)82590
Withdrew: Adverse event010
Withdrew: Lost to follow-up020
Withdrew: Physician decision010
Withdrew: Logistical problems020
Withdrew: Protocol deviation010
Withdrew: Withdrawal by subject020
Re-treatment Phase
Participant flow — Re-treatment Phase
MilestoneNilotinib 24-month TreatmentNilotinib 36-month TreatmentNot Randomized
Started74550
Completed58460
Not completed1690
Withdrew: Adverse event840
Withdrew: Death110
Withdrew: Administrative problems110
Withdrew: Withdrawal by subject510
Withdrew: Unstable mr100
Withdrew: Physician decision010
Withdrew: Lost to follow-up010

Outcome measures

PrimaryPercentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse 12 Months After Entering the TFR Phase

Number of participants who remained in TFR (≥molecular response (MR) 4.0) without molecular relapse 12 months after entering the TFR phase (without re-starting nilotinib therapy) divided by the number of participants who entered the TFR phase and multiplied by 100. Molecular relapse during TFR is defined as the loss of major molecular response (MMR), or the confirmed loss of MR4.0 (defined by 3 consecutive tests less than MR4.0 assessed at 3 consecutive visits during TFR phase). Participants dropping out early from the study during the TFR phase were considered as unsuccessful TFR. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL. MR4.0 is defined as either detectable disease≤0.01% BCR-ABL or undetectable disease in cDNA with≥10,000 ABL transcripts

Time frame:
12 months after entering the TFR phase, which is after 36 months from study treatment start for Nilotinib 24-month treatment arm and after 48 months from study treatment start for Nilotinib 36-month treatment arm
Reported as:
Number · Percentage of participants
Percentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse 12 Months After Entering the TFR Phase
Percentage of participantsNilotinib 24-month TreatmentNilotinib 36-month Treatment
Percentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse 12 Months After Entering the TFR Phase31.9 (23.7 to 41.1)37.5 (28.2 to 47.5)
Statistical analysis
  • Nilotinib 24-month Treatment vs Nilotinib 36-month Treatment · Chi-squared · p = 0.383
SecondaryCumulative Incidence of MMR During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry

Number of participants who were in MMR during pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.

Time frame:
From baseline up to 24 months after study treatment start
Reported as:
Number · Percentage of participants
Cumulative Incidence of MMR During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry
Percentage of participantsNilotinib 24-month TreatmentNilotinib 36-month TreatmentNot Randomized
Up to 3 months after study treatment start (pre-randomization)69.6 (47.1 to 86.8)37.5 (15.2 to 64.6)29.6 (20.8 to 39.7)
Up to 6 months after study treatment start (pre-randomization)100 (85.2 to 100.0)100.0 (79.4 to 100.0)64.3 (54.0 to 73.7)
Up to 9 months after study treatment start (pre-randomization)100 (85.2 to 100.0)100.0 (79.4 to 100.0)71.4 (61.4 to 80.1)
Up to 12 months after study treatment start (pre-randomization)100 (85.2 to 100.0)100.0 (79.4 to 100.0)77.6 (68.0 to 85.4)
Up to 15 months after study treatment start (pre-randomization)100 (85.2 to 100.0)100.0 (79.4 to 100.0)80.6 (71.4 to 87.9)
Up to 18 months after study treatment start (pre-randomization)100 (85.2 to 100.0)100.0 (79.4 to 100.0)82.7 (73.7 to 89.6)
Up to 21 months after study treatment start (pre-randomization)100 (85.2 to 100.0)100.0 (79.4 to 100.0)85.7 (77.2 to 92.0)
Up to 24 months after study treatment start (pre-randomization)100 (85.2 to 100.0)100.0 (79.4 to 100.0)86.7 (78.4 to 92.7)
SecondaryCumulative Incidence of MMR During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry

Number of participants who were in MMR during post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.

Time frame:
From randomization (month 24 after study treatment start) up to 36 months after study treatment start
Reported as:
Number · Percentage of participants
Cumulative Incidence of MMR During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry
Percentage of participantsNilotinib 36-month Treatment
Up to 27 months after study treatment start (post-randomization)100.0 (79.4 to 100.0)
Up to 30 months after study treatment start (post-randomization)100.0 (79.4 to 100.0)
Up to 33 months after study treatment start (post-randomization)100.0 (79.4 to 100.0)
Up to 36 months after study treatment start (post-randomization)100.0 (79.4 to 100.0)
SecondaryCumulative Incidence of MR4.0 During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry

Number of participants who were in MR4.0 during the pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

Time frame:
From baseline up to 24 months after study treatment start
Reported as:
Number · Percentage of participants
Cumulative Incidence of MR4.0 During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry
Percentage of participantsNilotinib 24-month TreatmentNilotinib 36-month TreatmentNot Randomized
Up to 3 months after study treatment start (pre-randomization)48.9 (38.3 to 59.6)38.3 (28.5 to 48.9)12.9 (9.6 to 16.8)
Up to 6 months after study treatment start (pre-randomization)85.9 (77.1 to 92.3)81.9 (72.6 to 89.1)26.6 (22.1 to 31.5)
Up to 9 months after study treatment start (pre-randomization)94.6 (87.8 to 98.2)92.6 (85.3 to 97.0)34.5 (29.5 to 39.6)
Up to 12 months after study treatment start (pre-randomization)96.7 (90.8 to 99.3)98.9 (94.2 to 100.0)39.2 (34.1 to 44.5)
Up to 15 months after study treatment start (pre-randomization)100.0 (96.1 to 100.0)98.9 (94.2 to 100.0)42.0 (36.8 to 47.3)
Up to 18 months after study treatment start (pre-randomization)100.0 (96.1 to 100.0)100.0 (96.2 to 100.0)45.1 (39.9 to 50.4)
Up to 21 months after study treatment start (pre-randomization)100.0 (96.1 to 100.0)100.0 (96.2 to 100.0)48.7 (43.4 to 54.1)
Up to 24 months after study treatment start (pre-randomization)100.0 (96.1 to 100.0)100.0 (96.2 to 100.0)52.1 (46.8 to 57.4)
SecondaryCumulative Incidence of MR4.0 During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry

Number of participants who were in MR4.0 during the post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

Time frame:
From randomization (month 24 after study treatment start) up to 36 months after study treatment start
Reported as:
Number · Percentage of participants
Cumulative Incidence of MR4.0 During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry
Percentage of participantsNilotinib 36-month Treatment
Up to 27 months after study treatment start (post-randomization)97.9 (92.5 to 99.7)
Up to 30 months after study treatment start (post-randomization)97.9 (92.5 to 99.7)
Up to 33 months after study treatment start (post-randomization)97.9 (92.5 to 99.7)
Up to 36 months after study treatment start (post-randomization)97.9 (92.5 to 99.7)
SecondaryCumulative Incidence of MR4.5 During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry

Number of participants who were in MR4.5 during the pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

Time frame:
From baseline up to 24 months after study treatment start
Reported as:
Number · Percentage of participants
Cumulative Incidence of MR4.5 During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry
Percentage of participantsNilotinib 24-month TreatmentNilotinib 36-month TreatmentNot Randomized
Up to 3 months after study treatment start (pre-randomization)21.1 (13.9 to 30.0)17.4 (10.8 to 25.9)4.0 (2.3 to 6.5)
Up to 6 months after study treatment start (pre-randomization)38.5 (29.4 to 48.3)38.5 (29.4 to 48.3)8.6 (5.9 to 11.9)
Up to 9 months after study treatment start (pre-randomization)57.8 (48.0 to 67.2)54.1 (44.3 to 63.7)10.7 (7.8 to 14.3)
Up to 12 months after study treatment start (pre-randomization)70.6 (61.2 to 79.0)65.1 (55.4 to 74.0)14.2 (10.8 to 18.1)
Up to 15 months after study treatment start (pre-randomization)79.8 (71.1 to 86.9)76.1 (67.0 to 83.8)15.2 (11.8 to 19.3)
Up to 18 months after study treatment start (pre-randomization)83.5 (75.2 to 89.9)80.7 (72.1 to 87.7)16.6 (13.0 to 20.7)
Up to 21 months after study treatment start (pre-randomization)85.3 (77.3 to 91.4)84.4 (76.2 to 90.6)18.4 (14.7 to 22.8)
Up to 24 months after study treatment start (pre-randomization)89.0 (81.6 to 94.2)89.0 (81.6 to 94.2)20.3 (16.4 to 24.8)
SecondaryCumulative Incidence of MR4.5 During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry

Number of participants who were in MR4.5 during the post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

Time frame:
From randomization (month 24 after study treatment start) up to 36 months after study treatment start
Reported as:
Number · Percentage of participants
Cumulative Incidence of MR4.5 During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry
Percentage of participantsNilotinib 36-month Treatment
Up to 27 months after study treatment start (post-randomization)70.6 (61.2 to 79.0)
Up to 30 months after study treatment start (post-randomization)76.1 (67.0 to 83.8)
Up to 33 months after study treatment start (post-randomization)84.4 (76.2 to 90.6)
Up to 36 months after study treatment start (post-randomization)87.2 (79.4 to 92.8)
SecondaryCumulative Incidence of MMR During the Pre-randomization Induction/Consolidation Phase

Number of participants who were in MMR during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.

Time frame:
From baseline up to 24 months after study treatment start
Reported as:
Number · Percentage of participants
Cumulative Incidence of MMR During the Pre-randomization Induction/Consolidation Phase
Percentage of participantsNilotinib 24-month TreatmentNilotinib 36-month TreatmentNot Randomized
Baseline80.8 (72.6 to 87.4)86.4 (78.9 to 92.1)74.3 (69.6 to 78.6)
Up to 3 months after study treatment start (pre-randomization)94.2 (88.4 to 97.6)91.5 (85.0 to 95.9)81.9 (77.7 to 85.6)
Up to 6 months after study treatment start (pre-randomization)100.0 (97.0 to 100.0)100.0 (96.9 to 100.0)90.8 (87.5 to 93.5)
Up to 9 months after study treatment start (pre-randomization)100.0 (97.0 to 100.0)100.0 (96.9 to 100.0)92.7 (89.6 to 95.1)
Up to 12 months after study treatment start (pre-randomization)100.0 (97.0 to 100.0)100.0 (96.9 to 100.0)94.2 (91.4 to 96.4)
Up to 15 months after study treatment start (pre-randomization)100.0 (97.0 to 100.0)100.0 (96.9 to 100.0)95.0 (92.3 to 97.0)
Up to 18 months after study treatment start (pre-randomization)100.0 (97.0 to 100.0)100.0 (96.9 to 100.0)95.5 (93.0 to 97.4)
Up to 21 months after study treatment start (pre-randomization)100.0 (97.0 to 100.0)100.0 (96.9 to 100.0)96.3 (93.9 to 98.0)
Up to 24 months after study treatment start (pre-randomization)100.0 (97.0 to 100.0)100.0 (96.9 to 100.0)96.6 (94.2 to 98.2)
SecondaryCumulative Incidence of MMR During the Post-randomization Consolidation Phase

Number of participants who were in MMR during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.

Time frame:
From randomization (month 24 after study treatment start) up to 36 months after study treatment start
Reported as:
Number · Percentage of participants
Cumulative Incidence of MMR During the Post-randomization Consolidation Phase
Percentage of participantsNilotinib 36-month Treatment
Up to 27 months after study treatment start (post-randomization)98.3 (94.0 to 99.8)
Up to 30 months after study treatment start (post-randomization)98.3 (94.0 to 99.8)
Up to 33 months after study treatment start (post-randomization)98.3 (94.0 to 99.8)
Up to 36 months after study treatment start (post-randomization)98.3 (94.0 to 99.8)
SecondaryCumulative Incidence of MR4.0 During the Pre-randomization Induction/Consolidation Phase

Number of participants who were in MR4.0 during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

Time frame:
From baseline up to 24 months after study treatment start
Reported as:
Number · Percentage of participants
Cumulative Incidence of MR4.0 During the Pre-randomization Induction/Consolidation Phase
Percentage of participantsNilotinib 24-month TreatmentNilotinib 36-month TreatmentNot Randomized
Baseline23.3 (16.1 to 31.9)20.3 (13.5 to 28.7)6.3 (4.1 to 9.2)
Up to 3 months after study treatment start (pre-randomization)60.8 (51.5 to 69.6)50.8 (41.5 to 60.2)18.4 (14.6 to 22.6)
Up to 6 months after study treatment start (pre-randomization)89.2 (82.2 to 94.1)85.6 (77.9 to 91.4)31.2 (26.6 to 36.2)
Up to 9 months after study treatment start (pre-randomization)95.8 (90.5 to 98.6)94.1 (88.2 to 97.6)38.6 (33.7 to 43.7)
Up to 12 months after study treatment start (pre-randomization)97.5 (92.9 to 99.5)99.2 (95.4 to 100.0)43.0 (38.0 to 48.2)
Up to 15 months after study treatment start (pre-randomization)100.0 (97.0 to 100.0)99.2 (95.4 to 100.0)45.7 (40.6 to 50.8)
Up to 18 months after study treatment start (pre-randomization)100.0 (97.0 to 100.0)100.0 (96.9 to 100.0)48.6 (43.4 to 53.7)
Up to 21 months after study treatment start (pre-randomization)100.0 (97.0 to 100.0)100.0 (96.9 to 100.0)52.0 (46.8 to 57.1)
Up to 24 months after study treatment start (pre-randomization)100.0 (97.0 to 100.0)100.0 (96.9 to 100.0)55.1 (50.0 to 60.2)
SecondaryCumulative Incidence of MR4.0 During the Post-randomization Consolidation Phase

Number of participants who were in MR4.0 during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

Time frame:
From randomization (month 24 after study treatment start) up to 36 months after study treatment start
Reported as:
Number · Percentage of participants
Cumulative Incidence of MR4.0 During the Post-randomization Consolidation Phase
Percentage of participantsNilotinib 36-month Treatment
Up to 27 months after study treatment start (post-randomization)98.3 (94.0 to 99.8)
Up to 30 months after study treatment start (post-randomization)98.3 (94.0 to 99.8)
Up to 33 months after study treatment start (post-randomization)98.3 (94.0 to 99.8)
Up to 36 months after study treatment start (post-randomization)98.3 (94.0 to 99.8)
SecondaryCumulative Incidence of MR4.5 During the Pre-randomization Induction/Consolidation Phase

Number of participants who were in MR4.5 during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

Time frame:
From baseline up to 24 months after study treatment start
Reported as:
Number · Percentage of participants
Cumulative Incidence of MR4.5 During the Pre-randomization Induction/Consolidation Phase
Percentage of participantsNilotinib 24-month TreatmentNilotinib 36-month TreatmentNot Randomized
Baseline9.2 (4.7 to 15.8)7.6 (3.6 to 14.0)1.8 (0.7 to 3.8)
Up to 3 months after study treatment start (pre-randomization)28.3 (20.5 to 37.3)23.7 (16.4 to 32.4)5.8 (3.7 to 8.6)
Up to 6 months after study treatment start (pre-randomization)44.2 (35.1 to 53.5)43.2 (34.1 to 52.7)10.2 (7.4 to 13.7)
Up to 9 months after study treatment start (pre-randomization)61.7 (52.4 to 70.4)57.6 (48.2 to 66.7)12.3 (9.2 to 16.1)
Up to 12 months after study treatment start (pre-randomization)73.3 (64.5 to 81.0)67.8 (58.6 to 76.1)15.7 (12.2 to 19.8)
Up to 15 months after study treatment start (pre-randomization)81.7 (73.6 to 88.1)78.0 (69.4 to 85.1)16.8 (13.2 to 20.9)
Up to 18 months after study treatment start (pre-randomization)85.0 (77.3 to 90.9)82.2 (74.1 to 88.6)18.1 (14.4 to 22.4)
Up to 21 months after study treatment start (pre-randomization)86.7 (79.3 to 92.2)85.6 (77.9 to 91.4)19.9 (16.1 to 24.3)
Up to 24 months after study treatment start (pre-randomization)90.0 (83.2 to 94.7)89.8 (82.9 to 94.6)21.8 (17.7 to 26.3)
SecondaryCumulative Incidence of MR4.5 During the Post-randomization Consolidation Phase

Number of participants who were in MR4.5 during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

Time frame:
From randomization (month 24 after study treatment start) up to 36 months after study treatment start
Reported as:
Number · Percentage of participants
Cumulative Incidence of MR4.5 During the Post-randomization Consolidation Phase
Percentage of participantsNilotinib 36-month Treatment
Up to 27 months after study treatment start (post-randomization)72.9 (63.9 to 80.7)
Up to 30 months after study treatment start (post-randomization)78.0 (69.4 to 85.1)
Up to 33 months after study treatment start (post-randomization)85.6 (77.9 to 91.4)
Up to 36 months after study treatment start (post-randomization)88.1 (80.9 to 93.4)
SecondaryPercentage of Participants Who Were in MMR During TFR Phase

Number of participants who were in MMR at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL.

Time frame:
From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were in MMR During TFR Phase
Percentage of participantsNilotinib 24-month TreatmentNilotinib 36-month Treatment
Month 1 after entering TFR phase97.5 (92.8 to 99.5)94.2 (87.9 to 97.9)
Month 2 after entering TFR phase84.9 (77.2 to 90.8)80.8 (71.9 to 87.8)
Month 3 after entering TFR phase62.2 (52.8 to 70.9)61.5 (51.5 to 70.9)
Month 4 after entering TFR phase51.3 (41.9 to 60.5)53.8 (43.8 to 63.7)
Month 5 after entering TFR phase45.4 (36.2 to 54.8)46.2 (36.3 to 56.2)
Month 6 after entering TFR phase42.9 (33.8 to 52.3)43.3 (33.6 to 53.4)
Month 8 after entering TFR phase40.3 (31.5 to 49.7)43.3 (33.6 to 53.4)
Month 10 after entering TFR phase38.7 (29.9 to 48.0)42.3 (32.7 to 52.4)
Month 12 after entering TFR phase36.1 (27.5 to 45.5)39.4 (30.0 to 49.5)
Month 15 after entering TFR phase35.3 (26.8 to 44.6)39.4 (30.0 to 49.5)
Month 18 after entering TFR phase35.3 (26.8 to 44.6)39.4 (30.0 to 49.5)
Month 21 after entering TFR phase34.5 (26.0 to 43.7)38.5 (29.1 to 48.5)
Month 24 after entering TFR phase31.9 (23.7 to 41.1)35.6 (26.4 to 45.6)
Month 27 after entering TFR phase31.9 (23.7 to 41.1)—
Month 30 after entering TFR phase31.9 (23.7 to 41.1)—
Month 33 after entering TFR phase30.3 (22.2 to 39.4)—
Month 36 after entering TFR phase23.5 (16.2 to 32.2)—
SecondaryPercentage of Participants Who Were in MR4.0 During the TFR Phase

Number of participants who were in MR4.0 at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

Time frame:
From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotininb 36-months treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-months treatment arm
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were in MR4.0 During the TFR Phase
Percentage of participantsNilotinib 24-month TreatmentNilotinib 36-month Treatment Arm
Month 1 after entering TFR phase87.4 (80.1 to 92.8)83.7 (75.1 to 90.2)
Month 2 after entering TFR phase58.0 (48.6 to 67.0)56.7 (46.7 to 66.4)
Month 3 after entering TFR phase39.5 (30.7 to 48.9)42.3 (32.7 to 52.4)
Month 4 after entering TFR phase36.1 (27.5 to 45.5)42.3 (32.7 to 52.4)
Month 5 after entering TFR phase32.8 (24.5 to 42.0)41.3 (31.8 to 51.4)
Month 6 after entering TFR phase33.6 (25.2 to 42.9)38.5 (29.1 to 48.5)
Month 8 after entering TFR phase34.5 (26.0 to 43.7)40.4 (30.9 to 50.5)
Month 10 after entering TFR phase35.3 (26.8 to 44.6)38.5 (29.1 to 48.5)
Month 12 after entering TFR phase31.9 (23.7 to 41.1)37.5 (28.2 to 47.5)
Month 15 after entering TFR phase34.5 (26.0 to 43.7)34.6 (25.6 to 44.6)
Month 18 after entering TFR phase33.6 (25.2 to 42.9)38.5 (29.1 to 48.5)
Month 21 after entering TFR phase30.3 (22.2 to 39.4)32.7 (23.8 to 42.6)
Month 24 after entering TFR phase29.4 (21.4 to 38.5)30.8 (22.1 to 40.6)
Month 27 after entering TFR phase31.1 (22.9 to 40.2)—
Month 30 after entering TFR phase30.3 (22.2 to 39.4)—
Month 33 after entering TFR phase27.7 (19.9 to 36.7)—
Month 36 after entering TFR phase26.1 (18.4 to 34.9)—
SecondaryPercentage of Participants Who Were in MR4.5 During the TFR Phase

Number of participants who were in MR4.5 at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

Time frame:
From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotininb 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were in MR4.5 During the TFR Phase
Percentage of participantsNilotinib 24-month TreatmentNilotinib 36-month Treatment Arm
Month 3 after entering TFR phase21.8 (14.8 to 30.4)26.9 (18.7 to 36.5)
Month 6 after entering TFR phase17.6 (11.3 to 25.7)28.8 (20.4 to 38.6)
Month 12 after entering TFR phase20.2 (13.4 to 28.5)26.9 (18.7 to 36.5)
Month 15 after entering TFR phase18.5 (12.0 to 26.6)23.1 (15.4 to 32.4)
Month 18 after entering TFR phase25.2 (17.7 to 34.0)26.9 (18.7 to 36.5)
Month 21 after entering TFR phase22.7 (15.5 to 31.3)22.1 (14.6 to 31.3)
Month 24 after entering TFR phase24.4 (17.0 to 33.1)20.2 (13.0 to 29.2)
Month 27 after entering TFR phase21.8 (14.8 to 30.4)—
Month 30 after entering TFR phase22.7 (15.5 to 31.3)—
Month 33 after entering TFR phase19.3 (12.7 to 27.6)—
Month 36 after entering TFR phase16.8 (10.6 to 24.8)—
SecondaryBCR-ABL Ratio (Expressed as a Percentage) During the Induction/Consolidation Phase

BCR-ABL transcript ratio by international scale (IS) (expressed as a percentage) during the induction/consolidation phase. Participants randomized to Nilotinib 36-month treatment arm had 12-month additional consolidation phase (post-randomization).

Time frame:
From baseline up to 24 months after study treatment start for Nilotinib 24-month treatment arm and Not randomized participants; and up to 36 months after study treatment start for Nilotinib 36-month treatment arm.
Reported as:
Mean · Percentage
BCR-ABL Ratio (Expressed as a Percentage) During the Induction/Consolidation Phase
PercentageNilotinib 24-month TreatmentNilotinib 36-month Treatment ArmNot Randomized
Baseline0.1367 ± 0.551440.0633 ± 0.127900.5509 ± 3.94256
Month 3 after study treatment start (pre-randomization)0.0106 ± 0.026600.0086 ± 0.011550.0728 ± 0.22537
Month 6 after study treatment start (pre-randomization)0.0052 ± 0.006310.0124 ± 0.055080.0530 ± 0.09587
Month 9 after study treatment start (pre-randomization)0.0049 ± 0.008090.0046 ± 0.005440.0573 ± 0.13905
Month 12 after study treatment start (pre-randomization)0.0044 ± 0.006110.0037 ± 0.004400.0772 ± 0.56398
Month 15 after study treatment start (pre-randomization)0.0035 ± 0.005910.0034 ± 0.003890.0669 ± 0.37209
Month 18 after study treatment start (pre-randomization)0.0029 ± 0.003540.0034 ± 0.004090.0462 ± 0.12284
Month 21 after study treatment start (pre-randomization)0.0028 ± 0.003190.0031 ± 0.002880.0390 ± 0.08271
Month 24 after study treatment start (pre-randomization)0.0027 ± 0.004240.0029 ± 0.003190.0325 ± 0.05140
Month 27 after study treatment start (post-randomization)—0.0089 ± 0.06119—
Month 30 after study treatment start (post-randomization)—0.0111 ± 0.08672—
Month 33 after study treatment start (post-randomization)—0.0025 ± 0.00439—
Month 36 after study treatment start (post-randomization)—0.0025 ± 0.00338—
SecondaryBCR-ABL Ratio (Expressed as a Percentage) During the TFR Phase

BCR-ABL/control gene (ABL) transcript ratio by international scale (IS) (expressed as a percentage) during the TFR phase. BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase.

Time frame:
From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
Reported as:
Mean · Percentage
BCR-ABL Ratio (Expressed as a Percentage) During the TFR Phase
PercentageNilotinib 24-month TreatmentNilotinib 36-month Treatment Arm
Month 1 after entering the TFR phase0.0042 ± 0.006210.0074 ± 0.02130
Month 2 after entering the TFR phase0.1162 ± 0.356060.2122 ± 0.99372
Month 3 after entering the TFR phase1.3774 ± 9.719090.4754 ± 1.84649
Month 4 after entering the TFR phase0.2667 ± 0.803360.2506 ± 0.91197
Month 5 after entering the TFR phase0.1740 ± 0.761230.0801 ± 0.26739
Month 6 after entering the TFR phase0.2219 ± 1.518080.1095 ± 0.66322
Month 8 after entering the TFR phase0.0075 ± 0.014030.0042 ± 0.00742
Month 10 after entering the TFR phase0.0062 ± 0.012950.0039 ± 0.00680
Month 12 after entering the TFR phase0.0047 ± 0.006650.0027 ± 0.00357
Month 15 after entering the TFR phase0.0030 ± 0.003170.0043 ± 0.00555
Month 18 after entering the TFR phase0.0030 ± 0.003840.0027 ± 0.00330
Month 21 after entering the TFR phase0.0036 ± 0.004840.0041 ± 0.00495
Month 24 after entering the TFR phase0.0077 ± 0.029100.0047 ± 0.00691
Month 27 after entering the TFR phase0.0024 ± 0.00246—
Month 30 after entering the TFR phase0.0023 ± 0.00281—
Month 33 after entering the TFR phase0.0079 ± 0.02376—
Month 36 after entering the TFR phase0.0041 ± 0.00767—
SecondaryBCR-ABL Ratio (Expressed as a Percentage) During the Nilotinib Re-treatment Phase

BCR-ABL/control gene (ABL) transcript ratio by international scale (IS) (expressed as a percentage) during the nilotinib re-treatment phase. BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes.

Time frame:
From Day 1 after entering the re-treatment phase up to 24 months after entering re-treatment phase for Nilotinib 36-month treatment arm and 36 months after entering the re-treatment phase for Nilotinib 24-month treatment arm
Reported as:
Mean · Percentage
BCR-ABL Ratio (Expressed as a Percentage) During the Nilotinib Re-treatment Phase
PercentageNilotinib 24-month TreatmentNilotinib 36-month Treatment Arm
Day 1 after entering the re-treatment phase2.8246 ± 2.395960.6301 ± 0.74388
Week 6 after entering the re-treatment phase0.6276 ± 2.342310.3112 ± 0.60279
Month 3 after entering the re-treatment phase0.0311 ± 0.072650.0131 ± 0.02359
Month 6 after entering the re-treatment phase0.0095 ± 0.032960.0070 ± 0.01330
Month 9 after entering the re-treatment phase0.0259 ± 0.177660.0065 ± 0.01099
Month 12 after entering the re-treatment phase0.0088 ± 0.031900.0047 ± 0.00839
Month 15 after entering the re-treatment phase0.0061 ± 0.013220.0045 ± 0.01176
Month 18 after entering the re-treatment phase0.0105 ± 0.052050.0039 ± 0.00581
Month 21 after entering the re-treatment phase0.0051 ± 0.016990.0031 ± 0.00342
Month 24 after entering the re-treatment phase0.0038 ± 0.007560.0014 ± 0.00197
Month 27 after entering the re-treatment phase0.0033 ± 0.00439—
Month 30 after entering the re-treatment phase0.0113 ± 0.04446—
Month 33 after entering the re-treatment phase0.0029 ± 0.00541—
Month 36 after entering the re-treatment phase0.0005 ± NA—
SecondaryProgression-free Survival (PFS) During the TFR Phase of the Study.

PFS is defined as the time from the date of start of the nilotinib TFR phase to the date of acelerated phase/blast crisis (AP/BC) or death, whichever came first. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotini 24-month treatment arm had a maximum of 36 months of TFR phase. Patients not known to have recurred or died on or before the cut-off date for PFS analysis were censored at the date of their last assessment (cytogenetic, hematology or extramedullary) for patients who were on study, and at the date of last contact for patients who were in follow-up.

Time frame:
From the start of the TFR phase to progression to AP/BC or death up to 24 months after entering TFR phase for Nilotininb 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
Reported as:
Median · Months
Progression-free Survival (PFS) During the TFR Phase of the Study.
MonthsNilotinib 24-month TreatmentNilotinib 36-month Treatment Arm
Progression-free Survival (PFS) During the TFR Phase of the Study.NA (NA to NA)NA (NA to NA)
SecondaryTreatment -Free Survival (TFS) During the TFR Phase of the Study

TFS is defined as the time from the start of the TFR phase to the date of the earliest of the following: loss of MMR, confirmed loss of MR4.0,re-start of nilotinib treatment, progression to AP/BC, or death from any cause. Patients not known to have had any of the events on or before the cut-off date were censored at the earlier of the date of their last assessment for patients who were still on study and the date of last contact for patients who were in follow-up. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1%BCR-ABL. MR4.0 is defined as either detectable disease ≤0.01%BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL)

Time frame:
From the start of the TFR phase to the date of occurrence of treatment-free survival event, up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
Reported as:
Median · Months
Treatment -Free Survival (TFS) During the TFR Phase of the Study
MonthsNilotinib 24-month TreatmentNilotinib 36-month Treatment Arm
Treatment -Free Survival (TFS) During the TFR Phase of the Study4.1 (3.7 to 5.5)4.2 (3.7 to 19.7)
SecondaryOverall Survival (OS) Rate During the TFR Phase of the Study.

OS is defined as the time from start of the TFR phase to the time of death due to any cause. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotini 24-month treatment arm had a maximum of 36 months of TFR phase. For participants without any event on or before the cut-off date, survival time will be censored at the date of their last assessment for patients who are still on study, and at the date of last contact for patients who are in follow-up.

Time frame:
From the start of the TFR phase to death due to any cause, assessed up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
Reported as:
Median · Months
Overall Survival (OS) Rate During the TFR Phase of the Study.
MonthsNilotinib 24-month TreatmentNilotinib 36-month Treatment Arm
Overall Survival (OS) Rate During the TFR Phase of the Study.NA (NA to NA)NA (NA to NA)
Post-hocAll Collected Deaths

Deaths on-treatment were collected during the induction/consolidation phase (from the first dose of study drug to 30 days after study treatment discontinuation, assessed up to 24 months for Nilotinib 24-month treatment arm and Not randomized, and up to 36 months for Nilotinib 36-month treatment arm) and during the re-treatment phase (from the start date of the re-treatment phase to 30 days after study treatment discontinuation, assessed up to 36 months for Nilotinib 24-month treatment arm and up to 24 months for Nilotinib 36-month treatment arm). Total deaths were collected from first dose of study drug until end of study, up to maximum duration of 5 years

Time frame:
On-treatment deaths: induction/consolidation phase (up to 24 months or 36 months from treatment start, depending on arm) and re-treatment phase (up to 36 months or up to 24 months from re-treatment start, depending on arm). All deaths: up to 5 years
Reported as:
Count of participants · Participants
All Collected Deaths
ParticipantsNilotinib 24-month TreatmentNilotinib 36-month TreatmentNot Randomized
On-treatment deaths113
Total deaths1310

Adverse events

Collected over - Induction/consolidation phase: From the first dose of study drug to 30 days after study treatment discontinuation, assessed up to 24 months for Nilotinib 24-month treatment arm and Not randomized, and up to 36 months for Nilotinib 36-month treatment arm. - Re-treatment phase: From the start date of the re-treatment phase to 30 days after study treatment discontinuation, assessed up to 36 months for Nilotinib 24-month treatment arm and up to 24 months for Nilotinib 36-month treatment arm. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib 24-month Treatment1/120 (0.8%)33/120 (27.5%)97/120 (80.8%)
Nilotinib 36-month Treatment1/118 (0.8%)27/118 (22.9%)104/118 (88.1%)
Not Randomized3/381 (0.8%)76/381 (19.9%)280/381 (73.5%)
Total5/619 (0.8%)136/619 (22%)481/619 (77.7%)
Most frequent serious events
Showing 10 of 147
Most frequent serious events
EventNilotinib 24-month TreatmentNilotinib 36-month TreatmentNot RandomizedTotal
Atrial fibrillationCardiac disorders3/1202/1184/3819/619
CellulitisInfections and infestations1/1202/1180/3813/619
Acute coronary syndromeCardiac disorders2/1200/1181/3813/619
Myocardial infarctionCardiac disorders2/1200/1184/3816/619
OsteoarthritisMusculoskeletal and connective tissue disorders2/1200/1180/3812/619
DizzinessNervous system disorders2/1200/1180/3812/619
Angina pectorisCardiac disorders0/1200/1185/3815/619
Coronary artery diseaseCardiac disorders0/1200/1184/3814/619
Lymphadenopathy mediastinalBlood and lymphatic system disorders0/1201/1180/3811/619
Acute myocardial infarctionCardiac disorders0/1201/1182/3813/619
Most frequent other events
Showing 10 of 47
Most frequent other events
EventNilotinib 24-month TreatmentNilotinib 36-month TreatmentNot RandomizedTotal
HypertensionVascular disorders20/12025/11827/38172/619
PruritusSkin and subcutaneous tissue disorders15/12023/11857/38195/619
HypercholesterolaemiaMetabolism and nutrition disorders23/12020/11865/381108/619
Pain in extremityMusculoskeletal and connective tissue disorders12/12021/11826/38159/619
Lipase increasedInvestigations21/12010/11834/38165/619
RashSkin and subcutaneous tissue disorders21/12010/11841/38172/619
ConstipationGastrointestinal disorders19/12014/11825/38158/619
Alanine aminotransferase increasedInvestigations10/12018/11827/38155/619
ArthralgiaMusculoskeletal and connective tissue disorders17/12018/11827/38162/619
HeadacheNervous system disorders17/12012/11834/38163/619

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nilotinib 24-month TreatmentNilotinib 36-month TreatmentNot RandomizedTotal
<=18 years0000
Between 18 and 65 years10698308512
>=65 years142173108
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib 24-month TreatmentNilotinib 36-month TreatmentNot RandomizedTotal
Female4849129226
Male7270252394
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nilotinib 24-month TreatmentNilotinib 36-month TreatmentNot RandomizedTotal
Caucasian114112355581
Black0145
Asian0022
Native American0112
North African descent1012
Unknown0156
Other541322
08

Study locations

208 sites
  • Novartis Investigative Site
    Linz, Oberoesterreich A 4020, Austria
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Linz, 4010, Austria
  • Novartis Investigative Site
    Linz, A-4010, Austria
  • Novartis Investigative Site
    Rankweil, A-6830, Austria
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Sofia, 1756, Bulgaria
  • Novartis Investigative Site
    Varna, 9000, Bulgaria
  • Novartis Investigative Site
    Brno Bohunice, Czech Republic 625 00, Czechia
  • Novartis Investigative Site
    Hradec Kralove, CZE 500 05, Czechia
  • Novartis Investigative Site
    Holstebro, DK-7500, Denmark
  • Novartis Investigative Site
    Roskilde, 4000, Denmark
  • Novartis Investigative Site
    HUS Helsinki, FIN-00029, Finland
  • Novartis Investigative Site
    Bayonne, Bayonne Cedex 64109, France
  • Novartis Investigative Site
    Le Mans, Cedex 09 72037, France
  • Novartis Investigative Site
    Paris Cedex 10, Cedex 10 75475, France
  • Novartis Investigative Site
    Caen, Cedex 14033, France
  • Novartis Investigative Site
    Angers Cedex 1, 49033, France
  • Novartis Investigative Site
    Bordeaux Cedex, 33000, France
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Chalon sur Saône, 71321, France
  • Novartis Investigative Site
    Chambéry cedex, 73011, France
  • Novartis Investigative Site
    Clermont Ferrand cedex 1, 63003, France
  • Novartis Investigative Site
    Corbeil Essonnes, 91100, France
  • Novartis Investigative Site
    Dunkerque, 59240, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    La Roche sur Yon cedex 9, 85925, France
  • Novartis Investigative Site
    Lille cedex, 59020, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Lyon Cedex, 69373, France
  • Novartis Investigative Site
    Marseille, 13273, France
  • Novartis Investigative Site
    Metz, 57000, France
  • Novartis Investigative Site
    Metz, 57085, France
  • Novartis Investigative Site
    Mulhouse cedex, 68070, France
  • Novartis Investigative Site
    Nice Cedex, 06202, France
  • Novartis Investigative Site
    Paris, 75012, France
  • Novartis Investigative Site
    Perpignan, 66046, France
  • Novartis Investigative Site
    Pontoise, F-95300, France
  • Novartis Investigative Site
    Rouen Cedex 1, 76038, France
  • Novartis Investigative Site
    Saint Priest en Jarez, 42271, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Mannheim, Baden-Wuerttemberg 68305, Germany
  • Novartis Investigative Site
    Augsburg, 86150, Germany
  • Novartis Investigative Site
    Bayreuth, 95445, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Braunschweig, 38114, Germany
  • Novartis Investigative Site
    Bremen, 28177, Germany
  • Novartis Investigative Site
    Chemnitz, 09113, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Eisenach, 99817, Germany
  • Novartis Investigative Site
    Frankfurt, 60596, Germany
  • Novartis Investigative Site
    Georgsmarienhuette, 49124, Germany
  • Novartis Investigative Site
    Halle, 06110, Germany
  • Novartis Investigative Site
    Hamm, 59063, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Koeln, 50671, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Lütten-Klein, 18107, Germany
  • Novartis Investigative Site
    Magdeburg, 39104, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    Muenchen, 81241, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Nuernberg, 90449, Germany
  • Novartis Investigative Site
    Offenburg, 77654, Germany
  • Novartis Investigative Site
    Potsdam, 14467, Germany
  • Novartis Investigative Site
    Rostock, 18057, Germany
  • Novartis Investigative Site
    Rostock, 18059, Germany
  • Novartis Investigative Site
    Schorndorf, 73614, Germany
  • Novartis Investigative Site
    Schwäbisch-Hall, 74523, Germany
  • Novartis Investigative Site
    Stuttgart, 70174, Germany
  • Novartis Investigative Site
    Velbert, 42551, Germany
  • Novartis Investigative Site
    Westerstede, 26655, Germany
  • Novartis Investigative Site
    Wiesbaden, 65191, Germany
  • Novartis Investigative Site
    Wuerzburg, 97080, Germany
  • Novartis Investigative Site
    Athens, GR 115 27, Greece
  • Novartis Investigative Site
    Thessaloniki, GR 570 10, Greece
  • Novartis Investigative Site
    Athens, 106 76, Greece
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Patras, 265 00, Greece
  • Novartis Investigative Site
    Budapest, 1097, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Szeged, H 6725, Hungary
  • Novartis Investigative Site
    Alessandria, AL 15100, Italy
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Avellino, AV 83100, Italy
  • Novartis Investigative Site
    Bari, BA 70124, Italy
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    Cagliari, CA 09126, Italy
  • Novartis Investigative Site
    Cremona, CR 26100, Italy
  • Novartis Investigative Site
    Catania, CT 95100, Italy
  • Novartis Investigative Site
    Cona, FE 44100, Italy
  • Novartis Investigative Site
    San Giovanni Rotondo, FG 71013, Italy
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy

Showing the first 100 of 208 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Borghi L, Rosti G, Maggi A, Breccia M, Di Bona E, Iurlo A, La Barba G, Sportoletti P, Albano F, Galimberti S, Rivellini F, Cambrin GR, Capodanno I, Cuneo A, Bonifacio M, Sica S, Arcaini L, Capochiani E, Minotto C, Ciceri F, Crugnola M, Di Caprio L, Supekar S, Elena C, Baccarani M, Vegni E. Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. Front Oncol. 2021 May 26;11:638689. doi: 10.3389/fonc.2021.638689. eCollection 2021. PubMed 34123791 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Jul 2020, 86 months.

Results were first posted in Jul 2021, 1 year after primary completion.

Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's 86 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2012
First posted
Dec 6, 2012
StartActual
Apr 15, 2013
Primary completionActual
Jul 8, 2020
CompletionActual
Jul 8, 2020
Results first posted
Jul 15, 2021
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01743989
Responsible party
Sponsor
First posted
Dec 6, 2012
Start date
Apr 15, 2013
Primary completion
Jul 8, 2020
Completion
Jul 8, 2020
Results posted
Jul 15, 2021
Last update
Jul 15, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion